BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37027480)

  • 1. Computational prediction of MHC anchor locations guides neoantigen identification and prioritization.
    Xia H; McMichael J; Becker-Hapak M; Onyeador OC; Buchli R; McClain E; Pence P; Supabphol S; Richters MM; Basu A; Ramirez CA; Puig-Saus C; Cotto KC; Freshour SL; Hundal J; Kiwala S; Goedegebuure SP; Johanns TM; Dunn GP; Ribas A; Miller CA; Gillanders WE; Fehniger TA; Griffith OL; Griffith M
    Sci Immunol; 2023 Apr; 8(82):eabg2200. PubMed ID: 37027480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
    Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
    Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CD8
    Shinkawa T; Tokita S; Nakatsugawa M; Kikuchi Y; Kanaseki T; Torigoe T
    Oncoimmunology; 2021 Jan; 10(1):1870062. PubMed ID: 33537174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
    Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
    Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
    Plewa N; Poncette L; Blankenstein T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation position is an important determinant for predicting cancer neoantigens.
    Capietto AH; Jhunjhunwala S; Pollock SB; Lupardus P; Wong J; Hänsch L; Cevallos J; Chestnut Y; Fernandez A; Lounsbury N; Nozawa T; Singh M; Fan Z; de la Cruz CC; Phung QT; Taraborrelli L; Haley B; Lill JR; Mellman I; Bourgon R; Delamarre L
    J Exp Med; 2020 Apr; 217(4):. PubMed ID: 31940002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Takazawa M; Ohara O; Nakajima J; Kakimi K
    Cancer Sci; 2017 Feb; 108(2):170-177. PubMed ID: 27960040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
    Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
    Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
    Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
    Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 19. Accounting for proximal variants improves neoantigen prediction.
    Hundal J; Kiwala S; Feng YY; Liu CJ; Govindan R; Chapman WC; Uppaluri R; Swamidass SJ; Griffith OL; Mardis ER; Griffith M
    Nat Genet; 2019 Jan; 51(1):175-179. PubMed ID: 30510237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
    Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.